In men with metastatic hormone-sensitive prostate cancer (mHSPC), the addition of enzalutamide to testosterone suppression continues to provide a significant improvement in overall survival (OS) after more than 5 years, according to an update from the phase 3 ENZAMET trial presented by Ian D. Davis, MBBS, PhD, FRACP, FAChPM, of Monash University and Eastern Health, in Australia, during the 2022...
See more from Catherine Marshall
Doublet therapy is here to stay for mHSPC – updated OS presented from ENZAMET.